 Evolus Inc NASDAQ: EOLS has announced that its strategic partner Daewoong Pharmaceutical Co. Ltd will pay Evolus 25.5 million in cash and eliminate 10.5 million of current and potential future milestone payments. Additionally, Daewoong will convert its debt into Evolus common shares, further reducing 40.5 million in convertible debt. 